Por: MarketWatch Business February 02, 2023
The company is expecting revenue to drop in 2023 amid a decline in sales of Lagevrio, its Covid-19 antiviral, and on Thursday set earnings guidance that was well below Wall Street expectations. Still, Merck Chief Financial Officer Caroline Litchfield said that the company’s core business, excluding Lagevrio, was strong and growing. “We have put out guidance for 2023 that continues the strong underlying growth of our business,” Litchfield... + full article
ABC News USA Business December 14, 2022
Moderna’s stock soared Tuesday after the COVID-19 vaccine maker detailed progress in developing a preventive shot for a deadly form of skin cancer.The company said a possible melanoma vaccine it is studying with pharmaceutical giant Merck fared well in a small study of... + más
Merck, Moderna detail potential skin cancer vaccine progress | WPLG Local 10
Merck, Moderna detail potential skin cancer vaccine progress | Associated Press
ABC News USA Health December 14, 2022
CBS News USA Health December 14, 2022
Moderna's stock soared Tuesday after the maker detailed progress in developing a preventive shot for a deadly form of .The company said a possible vaccine it is studying with pharmaceutical giant Merck fared well in a small study of patients who had the cancer surgically... + más
ABC7 USA Health December 14, 2022
.The company said a possible melanoma vaccine it is studying with pharmaceutical giant Merck fared well in a small study of patients who had the cancer surgically removed.The drugmakers said a combination of the vaccine and Merck's immunotherapy Keytruda led to a... + más
WPLG Local 10 USA Health December 13, 2022
Merck, Moderna detail potential skin cancer vaccine progress | ABC News
Associated Press USA Health December 13, 2022
MarketWatch USA Business October 27, 2022
“Three transactions shows deals can get done,” Litchfield says. “Where science and value align, we will act.” Merck shares were up 1.6% on Thursday, trading at a flat $100 per share, after the company that beat Wall Street expectations. Merck’s sales were $15 billion... + más
Moderna and Merck will jointly develop a cancer vaccine for high-risk melanoma patients | CNBC
Drugmaker Merck tops 3Q forecasts as Keytruda sales jump 20% | Associated Press
About iurex | Privacy Policy | Disclaimer |